# Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

> **NCT06232551** · NA · RECRUITING · sponsor: **Scott C. Woller, MD** · enrollment: 152000 (estimated)

## Conditions studied

- Venous Thromboembolic Disease
- Pulmonary Embolism and Thrombosis
- Deep Vein Thrombosis
- Hospitalism

## Interventions

- **OTHER:** EHR (electronic health record) alert
- **OTHER:** No EHR (electronic health record) alert

## Key facts

- **NCT ID:** NCT06232551
- **Lead sponsor:** Scott C. Woller, MD
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2025-01-15
- **Final completion:** 2025-09-30
- **Target enrollment:** 152000 (ESTIMATED)
- **Last updated:** 2024-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06232551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06232551, "Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06232551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*